Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) and Solana (NASDAQ:HSDT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Risk and Volatility
Nihon Kohden has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Solana has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
Insider and Institutional Ownership
0.1% of Nihon Kohden shares are owned by institutional investors. Comparatively, 18.6% of Solana shares are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Nihon Kohden | 6.08% | 9.46% | 6.68% |
| Solana | -1,427.15% | -67.57% | -24.09% |
Analyst Recommendations
This is a breakdown of current ratings for Nihon Kohden and Solana, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nihon Kohden | 0 | 1 | 0 | 1 | 3.00 |
| Solana | 1 | 1 | 1 | 1 | 2.50 |
Solana has a consensus target price of $3.50, indicating a potential upside of 95.53%. Given Solana’s higher probable upside, analysts clearly believe Solana is more favorable than Nihon Kohden.
Earnings & Valuation
This table compares Nihon Kohden and Solana”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nihon Kohden | $1.56 billion | 0.97 | $95.79 million | $0.59 | 15.34 |
| Solana | $6.02 million | 17.36 | -$40.89 million | ($109.67) | -0.02 |
Nihon Kohden has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.
Summary
Nihon Kohden beats Solana on 8 of the 14 factors compared between the two stocks.
About Nihon Kohden
Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.
About Solana
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for Nihon Kohden Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nihon Kohden and related companies with MarketBeat.com's FREE daily email newsletter.
